Bell Therapeutics, currently developing second-generation digital therapeutics (DTx), announced that it has entered into a research and development partnership with Professor Ki-Young Jung from the Department of Neurology at Seoul National University Hospital. This collaboration enables Bell Therapeutics to accelerate product advancement and clinical research, leveraging data and clinical expertise in the fields of sleep and neurological disorders.

Bell Therapeutics is pioneering DTx 2.0 to overcome the limitations of first-generation digital therapeutics. Unlike DTx 1.0, which replicates cognitive behavioral therapy (CBT) via software, DTx 2.0 is designed to mimic the mechanism of pharmaceuticals through software, providing immediate effects similar to medication without language dependency, which allows for high scalability in the market.

Jonghwa Park, CEO of Bell Therapeutics, stated, "While global interest in digital therapeutics is growing, it’s rare even among leading global companies to propose new therapeutic methods. Bell Therapeutics aims to establish itself as the company that makes the potential of digital therapeutics a reality by positioning fundamental scientific research and core technology development as its main competitive strengths, ultimately setting the standard for future digital therapeutics."

Professor Ki-Young Jung, former president of the Korean Sleep Society and the Korean Society for Electroencephalography, explained, "Bell Therapeutics' proprietary technology activates specific brain areas via software to regulate tension in the brain and body. This approach has distinct mechanisms compared to existing digital therapeutics, with potential for direct entry into the global medical market."

Professor Jung, a globally renowned authority in sleep medicine, has over 20 years of research experience on the pathogenesis and treatment of brain disorders, contributing to the early detection of REM sleep behavior disorder, an early symptom of dementia and Parkinson's disease.

Notably, this year Professor Jung became the first Korean to be awarded the Fellow Member title by the American Academy of Sleep Medicine (AASM) in recognition of his academic contributions. Through this partnership with Bell Therapeutics, he aims to advance domestic brain disease research to an international level.